Albaro José Nieto-Calvache

Albaro José Nieto-Calvache

Auto-generated profile, based on publicly available information

Albaro José Nieto-Calvache

Departamento de Ginecología y Obstetricia, Fundación Valle del Lili, Cali, Colombia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
PDF file
COCarlos Albert Ordoñez
Carlos Albert Ordoñez
RMRamiro Manzano-Nunez
Ramiro Manzano-Nunez
MPMichael W. Parra
Michael W. Parra
TRTodd E. Rasmussen
Todd E. Rasmussen
ANAlbaro J. Nieto
Albaro J. Nieto
MEMaria F. Escobar-Vidarte
Maria F. Escobar-Vidarte
BACKGROUND: We describe intraoperative and postdischarge outcomes of a case series after the prophylactic use of resuscitative endovascular balloon occlusion of the aorta (REBOA) during elective cesarean delivery in pregnant women with morbidly adherent placenta (MAP). We furthermore performed a systematic review and meta-analysis to investigate the safety and effectiveness of the use of REBOA during elective cesarean delivery in pregnant women with MAP. METHODS: Descriptive case series of REBOA (December 2015 to June 2017) used during elective cesarean delivery in pregnant women with MAP. The systematic review was conducted following PRISMA guidelines. We included studies involving pregnant women with a diagnosis of MAP who underwent an elective cesarean delivery with prophylactic REBOA placement. A meta-analysis was performed to assess the overall amount of transfusions and intraoperative hemorrhage of REBOA compared to NO-REBOA cases. RESULTS: A total of 12 patients with MAP underwent elective cesarean delivery with REBOA deployment. The median (interquartile range) of packed red blood cells transfused during the first 24 hours following surgery was two units (0–3.5). The median (interquartile range) of intraoperative blood loss was 1,500 mL (900–2,750). At 28 days, all patients were alive, and no adverse outcomes were observed. Four articles were included in the systematic review and meta-analysis. These articles included a total of 441 patients. Quantitative synthesis (meta-analysis) found that the use of REBOA as prophylaxis for the prevention of major hemorrhage was associated with a lower amount of intraoperative hemorrhage (in milliliters) (weighted mean difference, −1,384.66; 95% confidence interval, −2,141.74 to −627.58) and lower requirements of blood products transfusions (in units) (weighted mean difference, −2.42; 95% confidence interval, −3.90 to −0.94). CONCLUSION: We provide clinical data supporting the use of REBOA in the management of pregnant women with MAP undergoing elective cesarean delivery. Our findings demonstrate the feasibility of REBOA as a prophylactic intervention to improve outcomes in women at risk of catastrophic postpartum hemorrhage. LEVEL OF EVIDENCE: Therapeutic study, level V; Systematic Review, level IV.

11 November 2022 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Closed access
ANAlbaro José Nieto-Calvache
Albaro José Nieto-Calvache
JPJosé Miguel Palacios-Jaraquemada
José Miguel Palacios-Jaraquemada
RARozi Aryananda
Rozi Aryananda
NBNicolas Basanta
Nicolas Basanta
RARudy Aguilera
Rudy Aguilera
AMAdriana Messa
Adriana Messa

25 April 2021 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
ANAlbaro J. Nieto‐Calvache
Albaro J. Nieto‐Calvache
JPJose M. Palacios‐Jaraquemada
Jose M. Palacios‐Jaraquemada
GOGabriel Osanan
Gabriel Osanan
RCRafael Cortes‐Charry
Rafael Cortes‐Charry
RARozi Aditya Aryananda
Rozi Aditya Aryananda
TSthe Latin American group for the study of placenta accreta spectrum
the Latin American group for the study of placenta accreta spectrum

18 August 2022 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
TATheophilus K. Adu‐Bredu
Theophilus K. Adu‐Bredu
MRMarcus J. Rijken
Marcus J. Rijken
ANAlbaro Jose Nieto‐Calvache
Albaro Jose Nieto‐Calvache
VSVedran Stefanovic
Vedran Stefanovic
RARozi Aditya Aryananda
Rozi Aditya Aryananda
SCSally L. Collins
Sally L. Collins
Placenta accreta spectrum is a pregnancy complication associated with severe morbidity and maternal mortality especially when not suspected antenatally and appropriate management instigated. Women in resource‐limited settings are more likely to face adverse outcomes due to logistic, technical, and resource inadequacies. Accurate prenatal imaging is an important step in ensuring good outcomes because it allows adequate preparation and an appropriate management approach. This article provides a simple three‐step approach aimed at guiding clinicians and sonographers with minimal experience in placental accreta spectrum through risk stratification and basic prenatal screening for this condition both with and without Doppler ultrasound.

1 November 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
MEMaria Fernanda Escobar
Maria Fernanda Escobar
ANAlbaro J. Nieto
Albaro J. Nieto
SLSara Loaiza-Osorio
Sara Loaiza-Osorio
JBJuan S. Barona
Juan S. Barona
FRFernando Rosso
Fernando Rosso
In 2015 in Colombia, 60 pregnant women were hospitalized with chikungunya virus infections confirmed by reverse transcription PCR. Nine of these women required admission to the intensive care unit because of sepsis with hypoperfusion and organ dysfunction; these women met the criteria for severe acute maternal morbidity. No deaths occurred. Fifteen women delivered during acute infection; some received tocolytics to delay delivery until after the febrile episode and prevent possible vertical transmission. As recommended by a pediatric neonatologist, 12 neonates were hospitalized to rule out vertical transmission; no clinical findings suggestive of neonatal chikungunya virus infection were observed. With 36 women (60%), follow-up was performed 1 year after acute viremia; 13 patients had arthralgia in >2 joints (a relapse of infection). Despite disease severity, pregnant women with chikungunya should be treated in high-complexity obstetric units to rule out adverse outcomes. These women should also be followed up to treat potential relapses.

1 January 2022 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Closed access
ANAlbaro José Nieto-Calvache
Albaro José Nieto-Calvache
JPJosé Miguel Palacios-Jaraquemada
José Miguel Palacios-Jaraquemada
RARozi Aditya Aryananda
Rozi Aditya Aryananda
FRFernando Rodriguez
Fernando Rodriguez
COCarlos A. Ordoñez
Carlos A. Ordoñez
JBJuan Manuel Burgos
Juan Manuel Burgos